1006
Chemistry Letters Vol.35, No.9 (2006)
General and Convenient Approach to Flavan-3-ols:
Stereoselective Synthesis of (À)-Gallocatechin
Takashi Higuchi, Ken Ohmori, and Keisuke Suzukiꢀ
Department of Chemistry, Tokyo Institute of Technology, SORST-JST Agency,
O-okayama, Meguro-ku, Tokyo 152-8551
(Received June 9, 2006; CL-060668; E-mail: ksuzuki@chem.titech.ac.jp)
General synthetic route to flavan-3-ols was developed.
OBn
OBn
OBn
OBn
OBn
OBn
OBn
OBn
OBn
Union of two fragments was accomplished by an efficient
three-step protocol, enabling the stereoselective synthesis of
(ꢁ)-gallocatechin.
a
c
HO
HO
OH
O
HO
RO
b
4
3
5: R = H
6: R =
i-Pr
SO2
i-Pr
i-Pr
Considerable attention has recently been centered at the po-
tential bioactivities of flavan-3-ols (catechins). However, de-
tailed studies at molecular levels are hampered by their scarce
availability of pure samples, because the natural sources are gen-
erally comprised of hardly separable mixture of closely related
compounds. At this juncture, development of reliable synthetic
methods is of keen necessity.1,2
We have developed a concise synthetic route to this class
of compounds based on the assembly of two fragments for con-
structing the central pyran ring (Scheme 1). This communication
features the generality and the efficiency of the route by the
stereoselective synthesis of a highly oxygenated congener,
(ꢁ)-gallocatechin (1).3
Scheme 3. Conditions: (a) (DHQD)2PHAL (1 mol %), K3Fe-
(CN)6, K2CO3, K2OsO2(OH)4 (0.5 mol %), t-BuOH, H2O,
MeSO2NH2, 0 ꢂC, 92%, 99% ee; (b) 2,4,6-triisopropylbenzene-
1-sulfonyl chloride, pyridine, rt, 89%; (c) K2CO3, MeOH, 1,4-di-
oxane, 0 ꢂC, 90%; (DHQD)2PHAL = hydroquinidine 1,4-phthal-
azinediyl diether.
Conversely, we hoped that halohydrin II would be a good
substrate for Step 3, that is, the C–C bond formation to construct
the pyran ring (6-exo-tet). Two critical processes are relevant,
(1) the halogen–metal exchange (X ! Met) to generate aryl
anion species III, (2) displacement to form the pyran ring. The
first stage requires the chemoselectivity in that the other halogen
Y needs to remain intact.5,6
OH
OH
Scheme 3 shows the preparation of epoxide 3.7 Asymmetric
dihydroxylation of allyl alcohol 4 by using (DHQD)2PHAL8 as
the chiral ligand gave the corresponding triol 5 (92% yield, 99%
ee).9 Selective sulfonylation of the prim-hydroxy group in 510
followed by treatment with K2CO3 gave epoxide 3 in high yield.
Union of epoxyalcohol 3 with phenol 2 (X ¼ I) posed a ster-
eochemical challenge by the potentially facile loss of stereospe-
cificity (vide supra). Delightedly, however, the Mitsunobu reac-
tion11 gave us a clean solution to this issue. When epoxyalcohol
3 was allowed to react with Bu3P and TMAD,12 ether 7 was ob-
tained in 93% yield as a single diastereomer. Complete inversion
of the benzylic stereocenter was proven at a later stage.13 Oxir-
ane 7 was then regioselectively cleaved by Li2NiBr4,14 giving 8
in 98% yield, and the resulting alcohol was masked with TBS
group to afford bromide 9 in 93% yield (Scheme 4).
HO
O
O
OH
+
OH
OR
HO
(−)-gallocatechin (1)
Scheme 1. Retrosynthetic analysis.
Scheme 2 shows three critical steps. Step 1 involves union
of two building blocks, 2 and 3, through the C–O bond formation
in an inversion of the C(2) center. The anxiety was loss of the
stereochemical integrity, since the electron-rich aromatic ring
in 3 could strongly facilitate the SN1 ionization. Step 2 is the
opening of the oxirane ring to the corresponding halohydrin II,
since consideration of the Baldwin’s rule4 suggested the inade-
quacy of epoxide I as a substrate for the pyran ring closure
(6-endo-tet).
Faced with the pivotal transformation, i.e., construction of
the flavan skeleton from 9, we examined various reaction condi-
OBn
BnO
OBn
BnO
OH
X
step 1
O
Ar
2
OBn
+
HO
OBn
OBn
BnO
2
BnO
BnO
OBn
OBn
OBn
OBn
BnO
X
(X = I)
b
a
BnO
O
O
2
O
O
2
3
I
BnO
c
I
I
OR
3
step 2
Ar
step 3
O
Br
BnO
O
Ar
OR
7
8: R = H
9: R = TBS
i)
ii)
O
O
Ar
X
Met
OH
Scheme 4. Conditions: (a) TMAD, n-Bu3P, toluene, 0 ꢂC, 93%.
(b) Li2NiBr4, THF, 0 ꢂC, 98%; (c) TBSOTf, 2,6-di-t-butyl-
pyridine, CH2Cl2, 0 ꢂC, 93%; TMAD = N,N,N0,N0-tetramethyl-
azodicarboxamide, TBS = t-butyldimethylsilyl.
OR
BnO
Y
Y
III
IV
II
Scheme 2. Synthetic plan.
Copyright Ó 2006 The Chemical Society of Japan